Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.8 BRL | +4.49% | +2.56% | -34.19% |
Mar. 20 | Transcript : Blau Farmacêutica S.A., Q4 2023 Earnings Call, Mar 20, 2024 | |
Mar. 19 | Blau Farmacêutica S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 1.61B 313M | Sales 2025 * | 1.79B 348M | Capitalization | 1.92B 372M |
---|---|---|---|---|---|
Net income 2024 * | 210M 40.73M | Net income 2025 * | 260M 50.43M | EV / Sales 2024 * | 1.34 x |
Net Debt 2024 * | 246M 47.72M | Net Debt 2025 * | 328M 63.7M | EV / Sales 2025 * | 1.25 x |
P/E ratio 2024 * |
9.23
x | P/E ratio 2025 * |
7.54
x | Employees | 1,900 |
Yield 2024 * |
2.59% | Yield 2025 * |
3.12% | Free-Float | 16.44% |
Latest transcript on Blau Farmacêutica S.A.
1 day | +4.49% | ||
1 week | +2.56% | ||
Current month | +7.25% | ||
1 month | -10.00% | ||
3 months | -10.00% | ||
6 months | -25.77% | ||
Current year | -34.19% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 87-12-17 | |
Director of Finance/CFO | - | 18-04-30 | |
Roberto Altieri
CMP | Compliance Officer | - | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 61 | - | |
Chief Operating Officer | 58 | - | |
Founder | - | 87-12-17 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 0 M€ | +3.63% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 10.8 | -2.61% | 182,500 |
24-05-09 | 11.09 | +3.64% | 262,200 |
24-05-08 | 10.7 | +1.81% | 488,000 |
24-05-07 | 10.51 | +1.55% | 228,800 |
24-05-06 | 10.35 | -1.71% | 228,400 |
Delayed Quote Sao Paulo, May 10, 2024 at 04:07 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.19% | 372M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- BLAU3 Stock